EP4228643A1 - Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen - Google Patents

Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen

Info

Publication number
EP4228643A1
EP4228643A1 EP21880683.4A EP21880683A EP4228643A1 EP 4228643 A1 EP4228643 A1 EP 4228643A1 EP 21880683 A EP21880683 A EP 21880683A EP 4228643 A1 EP4228643 A1 EP 4228643A1
Authority
EP
European Patent Office
Prior art keywords
administered
range
zinc
vitamin
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21880683.4A
Other languages
English (en)
French (fr)
Other versions
EP4228643A4 (de
Inventor
Chee Seong SEET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University Hospital Singapore Pte Ltd
Original Assignee
National University Hospital Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Hospital Singapore Pte Ltd filed Critical National University Hospital Singapore Pte Ltd
Publication of EP4228643A1 publication Critical patent/EP4228643A1/de
Publication of EP4228643A4 publication Critical patent/EP4228643A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present disclosure relates to the field of general medicine, respiratory medicine, intensive care, and infectious diseases.
  • the present disclosure relates to a composition of matter and to a method for the prevention of coronavirus disease 2019 (COVID- 19) and respiratory tract infections arising from pathogens including viruses, bacteria, fungi, and parasites.
  • COVID- 19 coronavirus disease 2019
  • pathogens including viruses, bacteria, fungi, and parasites.
  • SARS-CoV-2 The novel coronavirus SARS-CoV-2 was recognised to cause the coronavirus disease 2019 (COVID-19).
  • SARS-CoV-2 and COVID-19 have recently spread rapidly across the globe. Tens of millions of people have been diagnosed with COVID-19, resulting in a staggering number of deaths.
  • Existing data suggests that COVID- 19 has a mortality rate of approximately 1-2%, with a higher mortality rate among individuals with pre-existing comorbidities and in healthcare systems with suboptimal access to ventilatory support.
  • Accumulating data suggests that the incubation period of SARS-CoV-2 is approximately 5-7 days, and a significant proportion of patients may remain asymptomatic or mildly symptomatic during the illness.
  • COVID-19 causes a mild and mostly self-limiting illness
  • severe pneumonia has been reported in about 5% of patients during the inflammation phase of the disease, thus leading to patients requiring supplemental oxygen and endotracheal ventilation.
  • Data from post-mortem studies indicate extensive alveolar damage, fibrosis, and consolidation in lung tissues of COVID- 19 patients.
  • the antiseptic povidone-iodine has rapid virucidal effects against SARS-CoV-2, while zinc inhibits replication of at least six coronaviruses (including SARS-CoV and others that cause common cold).
  • coronaviruses including SARS-CoV and others that cause common cold.
  • vitamin C is a widely used remedy during the COVID-19 pandemic.
  • AU 2020/100641 discloses oral administration of vitamin C and zinc in addition to azithromycin and aspirin.
  • AU 2020/100400 discloses the combination of lifestyle changes with oral administration of vitamin supplements and prescription medicines to reduce the risk of viral infections.
  • the vitamin supplements administered include nicotinamide, resveratrol, vitamin D3, while the prescription medicine administered was doxycycline and metformin.
  • US 2020/179367 discloses the administration of isomyosmine for the treatment of coronavirus infection.
  • a disadvantage of administration through the oral route is the first-pass effect and the delayed onset of action while the key advantage of administering drugs through the oropharyngeal and tracheobronchial routes lies in its potentially rapid onset of action at the main mode of entry for respiratory pathogens.
  • the present disclosure provides a composition of matter and a method for preventing respiratory tract infections arising from pathogens including viruses, bacteria, fungi, and parasites.
  • This includes the SARS-CoV-2 virus and COVID- 19, the disease caused by the SARS-CoV-2 virus.
  • An aspect of an embodiment of the disclosure relates to the administration of a combination of two or more pharmaceutical drugs or active ingredients by inhalation for a multipronged and multitargeted approach against the spread of COVID-19 in the respiratory system.
  • the two or more drugs or active ingredients may be administered through the oropharyngeal and tracheobronchial routes.
  • the two or more drugs or active ingredients may be provided in liquid or powder forms.
  • Administration through the nasal, oropharyngeal and tracheobronchial routes can be through direct contact, aerosolization or nebulisation methods to the nasal, nasopharynx, oropharynx, and tracheobronchial spaces.
  • composition of matter for delivery of a therapeutic amount per day of two or more substances to a patient through an inhalation delivery system for prevention or treatment of respiratory illness wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
  • the two or more substances may be delivered through the nasal tract, oropharyngeal tract, or the respiratory tract.
  • the two or more substances selected may be hydroxychloroquine and povidone -iodine.
  • the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of povidone -iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg.
  • the two or more substances selected may be hydroxychloroquine and zinc.
  • the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
  • the two or more substances selected may be hydroxychloroquine and vitamin C.
  • the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
  • the two or more substances selected may be hydroxychloroquine, vitamin C, and zinc.
  • the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg;
  • the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg;
  • the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
  • the two or more substances selected may be povidone-iodine and vitamin C.
  • the therapeutic amount per day of povidone-iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300- 400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800-1000 mg.
  • the two or more substances selected may be povidone-iodine and zinc.
  • the therapeutic amount per day of povidone-iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
  • the two or more substances selected may be povidone-iodine, zinc, and vitamin C.
  • the therapeutic amount per day of povidone- iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg;
  • the therapeutic amount of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60- 80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg;
  • the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
  • the two or more substances selected may be zinc and vitamin C.
  • the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800-1000 mg.
  • the therapeutic amount per day of hydroxychloroquine may be 0.00001-800 mg.
  • the therapeutic amount per day of hydroxychloroquine may be 1-800 mg.
  • the therapeutic amount per day of povidone-iodine maybe 1-600 pg.
  • the therapeutic amount per day of povidone-iodine is 89-356 pg.
  • the therapeutic amount per day of zinc may be 0.00001-200 mg.
  • the therapeutic amount per day of vitamin C may be 0.00001-2000 mg.
  • the therapeutic amount per day of vitamin C may be 0.00001- 1000 mg.
  • the inhalation delivery system may be selected from the group comprising of nebulisation, aerosolization and oral gargle.
  • delivery may be carried out based on a dosing regimen.
  • composition of two or more substances for use in the prevention or treatment of respiratory illness by inhalation wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
  • composition comprising two or more substances selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine for preventing or treating respiratory illness, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
  • the terms “plurality” and “a plurality” as used herein may include, for example, “multiple” or “two or more”.
  • the terms “plurality” or “a plurality” may be used throughout the specification to describe two or more components, devices, elements, units, parameters, or the like.
  • the method embodiments described herein are not constrained to a particular order or sequence. Additionally, some of the described method embodiments or elements thereof can occur or be performed simultaneously, at the same point in time, or concurrently. Unless otherwise indicated, use of the conjunction “or” as used herein is to be understood as inclusive (any or all of the stated options).
  • any doses of medication discussed and disclosed in the present disclosure refers to the total dose of each medication to be administered per day.
  • the total dose of each medication to be administered per day may be administered in a single dose a day or may be administered in multiple doses a day.
  • the present combination therapy is focused on the administration or delivery of a combination of two or more substances by inhalation.
  • the inhalation may be through the nasal, oropharyngeal and tracheobronchial routes.
  • the substances may be pharmaceutical drugs or active ingredients.
  • Delivery of a therapeutic agent by inhalation to the respiratory system using an inhalation delivery system allows for a direct delivery of medication to where the medication is needed and avoids the first-pass effect with minimum reduction of bioavailability.
  • the large surface area in the pulmonary region facilitates rapid absorption of the delivered drug from the alveolar region to the blood.
  • aerosol delivery is non-invasive, a much lower dose of medications is required to achieve the same efficacy compared to oral administration.
  • the two or more pharmaceutical drugs or active ingredients may be administered through the nasal, oropharyngeal or the tracheobronchial tract.
  • the two or more pharmaceutical drugs or active ingredients may be delivered to the nasal, nasopharynx, oropharynx, and tracheobronchial spaces.
  • the two or more pharmaceutical drugs or active ingredients may be administered through therapeutic inhalation delivery systems which facilitate the transport and deposition of drugs in the human respiratory tract.
  • the therapeutic inhalation delivery systems may be a pressurised metered-dose inhaler (MDI), a dry powder inhaler, a medical nebuliser, a solution mist inhaler, or an oral/nasal spray.
  • the therapeutic inhalation delivery system may differ depending on several factors, including particle characteristics (e.g., particle size, shape, density, charge and hygroscopicity), airway geometry (due to age, gender, and disease status), and breathing pattern (e.g., frequency, tidal volume, and breath-holding time).
  • particle characteristics e.g., particle size, shape, density, charge and hygroscopicity
  • airway geometry due to age, gender, and disease status
  • breathing pattern e.g., frequency, tidal volume, and breath-holding time
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, povidone-iodine, zinc, or vitamin C.
  • hydroxychloroquine may be administered within a range of 0.00001-800 mg per day, and preferably within a range of 1-800 mg per day.
  • povidone- iodine may be administered within a range of 1-600 pg a day.
  • povidone-iodine may be administered within a range of 1-4 sprays of a commercially available spray, which may amount to a range of 89-356 pg of povidone-iodine.
  • zinc may be administered within a range of 0.00001-200 mg per day.
  • vitamin C may be administered within a range of 0.00001-2000 mg per day, and preferably within a range of 0.00001-1000 mg per day.
  • the composition may be hydroxychloroquine with povidone-iodine, hydroxychloroquine with zinc, hydroxychloroquine with vitamin C, hydroxychloroquine with vitamin C and zinc, povidone- iodine with vitamin C, povidone-iodine with zinc, povidone-iodine with zinc and vitamin C, or zinc with vitamin C.
  • the dosage range may vary depending on several factors, including the therapeutic delivery system employed and characteristics of the recipient.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • povidone-iodine may be administered within a range of 1- 100 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • povidone-iodine may be administered within a range of 100-200 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 200-300 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • povidone-iodine may be administered within a range of 300-400 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • povidone-iodine may be administered within a range of 400-500 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • povidone-iodine may be administered within a range of 500-600 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 10-20 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 1-10 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 1-10 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 1-10 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 1-10 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 1-10 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 20-40 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 40-60 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 60-80 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 60-80 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 60-80 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 60-80 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 60-80 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 60-80 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 80-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 100-125 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 100-125 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 100-125 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 100-125 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 100-125 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 100-125 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 125-150 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 150-175 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 150-175 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 150-175 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 150-175 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 150-175 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 150-175 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 0.00001- 1 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
  • Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • zinc may be administered within a range of 175-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
  • Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1-10 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 0.00001-1 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 1-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1-10 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 1- 100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 1-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 1-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 1-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 1-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 1-100 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1-10 mg
  • vitamin C may be administered within a range of 100- 200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 100-200 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1-10 mg
  • vitamin C may be administered within a range of 200- 400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 200-400 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1-10 mg
  • vitamin C may be administered within a range of 400- 600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 400-600 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1-10 mg
  • vitamin C may be administered within a range of 600- 800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 600-800 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 0.00001-1 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 1- 10 mg
  • vitamin C may be administered within a range of 800- 1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 10-20 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 20-40 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 40-60 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 60-80 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 80-100 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 100-125 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 125-150 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 150-175 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
  • Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
  • zinc may be administered within a range of 175-200 mg
  • vitamin C may be administered within a range of 800-1,000 mg
  • the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range ofO.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
  • Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
  • vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
  • the two or more pharmaceutical drugs or active ingredients may be administered according to a dosage regimen, including administration one or more times a day.
  • a dosage regimen including administration one or more times a day.
  • the dosage regimen may vary depending on several factors, including the therapeutic delivery system employed, the pharmaceutical drug or active ingredient administered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21880683.4A 2020-10-15 2021-10-14 Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen Pending EP4228643A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202010250W 2020-10-15
PCT/SG2021/050621 WO2022081093A1 (en) 2020-10-15 2021-10-14 Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses

Publications (2)

Publication Number Publication Date
EP4228643A1 true EP4228643A1 (de) 2023-08-23
EP4228643A4 EP4228643A4 (de) 2025-10-15

Family

ID=81209491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21880683.4A Pending EP4228643A4 (de) 2020-10-15 2021-10-14 Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen

Country Status (2)

Country Link
EP (1) EP4228643A4 (de)
WO (1) WO2022081093A1 (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
US6004560A (en) * 1998-11-16 1999-12-21 Hsu; Wu-Ching Nasal spray (drop) for treating fever/cold, and its preparation
JP2002059700A (ja) * 2000-08-22 2002-02-26 Osaka Prefecture 虹色発色加工法
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20200289552A1 (en) * 2017-07-04 2020-09-17 Fluchem Ltd Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof
CN111297838A (zh) * 2020-04-08 2020-06-19 宁波合康生物医药科技有限公司 一种抗病毒药物的吸入喷雾剂
EP3892275A1 (de) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolisierung von hcq oder dessen metaboliten zur behandlung von lungeninfektionen
US20240299293A1 (en) * 2020-11-09 2024-09-12 Rucker Capital Advisors Oral rinse, nasal spray and methods for prevention of COVID-19 by lowering viral load of COVID-19

Also Published As

Publication number Publication date
EP4228643A4 (de) 2025-10-15
WO2022081093A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US5543434A (en) Nasal administration of ketamine to manage pain
CN108040468B (zh) 用于治疗口腔、咽喉和呼吸道疾病的制剂
KR20150096370A (ko) 항불안제 조성물, 제형 및 사용방법
CN111265500A (zh) 一种防治covid-19的药物组合物及其制备方法
US20230158259A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
EP4232073B1 (de) Neues dosierschema für inhaliertes vasoaktives intestinales polypeptid
Sher et al. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma
CN112791097A (zh) 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法
MX2014002125A (es) Tratamiento de sintomas asociados a gastroparesia femenina.
US20130216574A1 (en) Kit providing multiple unmet therapeutic effects
EP3393517B1 (de) Acetylsalicylsäure zur behandlung von moderater bis schwerer influenza
EP4228643A1 (de) Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen
CA2506962A1 (en) Synergistic combination comprising roflumilast and formoterol
JPH05201861A (ja) デキストロメトルフアンの鎮咳効果の増強
AU2020103517A4 (en) Ibp- nebulizer: intelligent nebulizer for bronchitis patients
Tomić et al. Medications and non-pharmacological measures to alleviate the symptoms of respiratory tract infections in the pediatric population
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
Amar et al. Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthma.
WO2022063320A1 (zh) 一种抑制呼吸道病毒的组合物及呼吸道病毒防治方法
CN1713902A (zh) 包含罗氟司特和(r,r)－福莫特罗的协同组合物
Thangaraju et al. Effectiveness of turmeric-based lozenges in reducing the postoperative sore throat and cough–A prospective randomized placebo-controlled study
Ballard et al. Assessment of bronchodilator response to a β-adrenergic delivered from an ultrasonic nebulizer
Zayed et al. Short term effects of nebulized epinephrine as a treatment of viral bronchiolitis
TW589185B (en) Pharmaceutical compositions for treating sinusitis and otitis media comprising corticosteroids
Almukhambetova et al. Nebulising therapy of bronchial asthma attacks

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20241009BHEP

Ipc: A61P 31/14 20060101ALI20241009BHEP

Ipc: A61P 11/00 20060101ALI20241009BHEP

Ipc: A61K 9/72 20060101ALI20241009BHEP

Ipc: A61K 33/30 20060101ALI20241009BHEP

Ipc: A61K 31/375 20060101ALI20241009BHEP

Ipc: A61K 33/18 20060101ALI20241009BHEP

Ipc: A61K 31/4706 20060101AFI20241009BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250911

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4706 20060101AFI20250905BHEP

Ipc: A61K 33/18 20060101ALI20250905BHEP

Ipc: A61K 31/375 20060101ALI20250905BHEP

Ipc: A61K 33/30 20060101ALI20250905BHEP

Ipc: A61K 9/72 20060101ALI20250905BHEP

Ipc: A61P 11/00 20060101ALI20250905BHEP

Ipc: A61P 31/14 20060101ALI20250905BHEP

Ipc: A61K 9/00 20060101ALI20250905BHEP